Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.07B -18.2%
Revenue (ttm)	493.25M +18.7%
Net Income	104.51M +16.3%
EPS	2.99 +3.8%
Shares Out	35.00M
PE Ratio	19.76
Forward PE	n/a
Dividend	1.38 (2.34%)
Ex-Dividend Date	Mar 30, 2026

Volume	337,984
Average Volume	152,709
Open	57.85
Previous Close	57.85
Day's Range	57.80 - 60.50
52-Week Range	53.89 - 79.09
Beta	0.49
RSI	51.08
Earnings Date	Aug 11, 2026

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. Its product portfolio includes dermatological, respiratory, cardiovascular, alimentary and anti-infectives, musculoskeletal, genitourinary systems, and CNS. It exports its products. The company was formerly known as Middle East Chemical Products Factory Compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 731
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2025, TADAWUL:4016's revenue was 460.48 million, an increase of 16.87% compared to the previous year's 394.00 million. Earnings were 97.01 million, an increase of 21.49%.